特发性肺纤维化治疗市场规模、份额和成长分析（按药物类别、给药途径、作用机制、分销管道、最终用途和地区）- 产业预测 2025-2032

特发性肺纤维化治疗市场规模在 2023 年价值 46 亿美元，预计将从 2024 年的 49.2 亿美元增长到 2032 年的 83.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

全球特发性肺纤维化 (IPF) 治疗市场正在经历显着增长，这主要是由于人口的增加和对呼吸系统疾病认识的提高。 IPF 的特征是肺部疤痕形成，影响呼吸，是肺纤维化的主要形式。目前的治疗方法包括FDA核准的药物疗法，例如尼达尼布和Pirfenidone，而肺移植仍是晚期疾病患者的有效解决方案。近年来，研发活动不断增多，带来了有前景的治疗方法创新和候选药物。此外，製药公司和研究机构之间的策略合作正在推动有效的 IPF治疗方法的开发，进一步推动市场活力并改善患者的治疗效果。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

特发性肺纤维化治疗市场规模（依药物类别和复合年增长率） (2025-2032)

• 市场概况
• Pirfenidone
• 尼达尼布
• 其他的

特发性肺纤维化治疗市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概况
• 口服
• 注射

特发性肺纤维化治疗市场规模（按作用机制和复合年增长率） (2025-2032)

• 市场概况
• 抗纤维化药物
• 蛋白酪氨酸激酶抑制剂
• 其他的

特发性肺纤维化治疗市场规模（按分销管道和复合年增长率）（2025-2032）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

特发性肺纤维化治疗市场规模（按最终用途和复合年增长率划分）（2025-2032 年）

• 市场概况
• 医院
• 诊所
• 居家照护

特发性肺纤维化治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Boehringer Ingelheim International GmbH（Germany）
• Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（UK）
• Biogen（USA）
• FibroGen, Inc.（USA）
• Bristol Myers Squibb Company（USA）
• GNI Group Ltd.（Japan）
• Cipla Inc.（India）
• Amgen Inc.（USA）
• Mission Therapeutics（UK）
• Galapagos NV（Belgium）
• Promedior, Inc.（USA）
• Zai Lab Limited（China）
• Pliant Therapeutics, Inc.（USA）
• Kadmon Holdings, Inc.（USA）
• Genentech, Inc.（USA）
• Sanofi（France）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• United Therapeutics Corporation（USA）

结论和建议

Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 4.92 billion in 2024 to USD 8.39 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global idiopathic pulmonary fibrosis (IPF) treatment market has seen substantial growth, primarily driven by an increasing population and heightened awareness of respiratory diseases. IPF, characterized by lung scarring that impairs breathing, is the predominant form of pulmonary fibrosis. Current treatment options include FDA-approved pharmacological therapies like Nintedanib and Pirfenidone, while lung transplantation remains a viable solution for patients in advanced stages of the disease. Recent years have witnessed a surge in R&D activities, resulting in promising therapeutic innovations and new drug candidates. Moreover, strategic collaborations between pharmaceutical companies and research institutions are propelling the development of effective IPF treatments, further invigorating market dynamics and enhancing patient care outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Idiopathic Pulmonary Fibrosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Idiopathic Pulmonary Fibrosis Treatment Market Segments Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented by Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use and region. Based on Drug Class, the market is segmented into Pirfenidone, Nintedanib and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End-use, the market is segmented into Hospitals, Clinics and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Idiopathic Pulmonary Fibrosis Treatment Market

A significant factor propelling the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the growing incidence of IPF, especially among the elderly demographic. As the disease becomes more common worldwide, there is an escalating demand for effective treatment modalities. This increase in diagnosed cases highlights the urgent need for pharmaceutical solutions and therapies that can not only decelerate the progression of the disease but also enhance the overall quality of life for patients. Consequently, the continual rise in the prevalence of IPF serves as a vital driver for the expansion and innovation within this treatment market.

Restraints in the Idiopathic Pulmonary Fibrosis Treatment Market

A significant challenge facing the idiopathic pulmonary fibrosis (IPF) treatment market is the prohibitive cost associated with therapies. The expenses tied to medications and diagnostic procedures can be substantial, potentially restricting access to essential treatments, particularly in areas where healthcare resources are scarce or insurance coverage is insufficient. This financial barrier can hinder the availability and affordability of effective therapeutic options, ultimately affecting patient outcomes and limiting the overall growth potential of the IPF treatment market in various regions, particularly those with less developed healthcare infrastructure. Addressing these cost-related issues is crucial for improving patient access to necessary care.

Market Trends of the Idiopathic Pulmonary Fibrosis Treatment Market

The idiopathic pulmonary fibrosis (IPF) treatment market is witnessing a significant shift towards personalized medicine and precision therapeutics, reflecting a broader trend in healthcare. As research progresses, the emphasis has moved from understanding the disease's pathogenesis to developing tailored treatment strategies aimed at individual patient profiles. Notable advancements in pharmacotherapy, particularly with the introduction of Nintedanib and Pirfenidone, have demonstrated efficacy in slowing the decline in forced vital capacity (FVC) and improving patient quality of life. This growing focus on individualized treatment plans is poised to drive market growth, as stakeholders aim to enhance therapeutic outcomes and optimize patient care in IPF management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Pirfenidone
• Nintedanib
• Others

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Mode of Action & CAGR (2025-2032)

• Market Overview
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Others

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare Settings

Global Idiopathic Pulmonary Fibrosis Treatment Market Size & CAGR (2025-2032)

• North America (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GNI Group Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mission Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promedior, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zai Lab Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pliant Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kadmon Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations